Key result
Intraoperative photodynamic therapy was feasible and safe in 10 patients with recurrent retroperitoneal sarcomas, with 2 patients remaining recurrence-free at 24 and 28 months.
Why the study?
Is intraoperative photodynamic therapy feasible and safe in patients with recurrent retroperitoneal sarcomas?
Population
10 patients with recurrent retroperitoneal sarcomas after conventional methods of treatment
Design
Case_series
Follow-up
up to 28 months
Authors
Loading...
Adjuvant PDT feasible after resection in recurrent retroperitoneal sarcomas; leaves open efficacy and warrants prospective trials.
Is intraoperative photodynamic therapy feasible and safe in patients with recurrent retroperitoneal sarcomas?
Intraoperative photodynamic therapy is a feasible adjuvant treatment for recurrent retroperitoneal sarcomas, though further evaluation of effectiveness is needed.
Nambisan et al. (1988) studied recurrent retroperitoneal sarcomas (n=10). Intraoperative photodynamic therapy (PDT) was evaluated on Feasibility and recurrence. Intraoperative photodynamic therapy was feasible and safe in 10 patients with recurrent retroperitoneal sarcomas, with 2 patients remaining recurrence-free at 24 and 28 months.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: